ライフサイエンスコーパス: pulmonary

1 Congenital pulmonary airway malformation (CPAM) is a relatively rar

2 ection of MARC-145 cells and primary porcine pulmonary alveolar macrophages led to significant reduct

3 ody surface areas with the highest levels of pulmonary and activation-regulated chemokine, tissue inh

4 Pulmonary and LP-derived epithelial cells expressed at b

5 cross-sectional, case-control study in U.S. pulmonary and primary care clinics that recruited subjec

6 tients with COPD and/or CS-exposed mice have pulmonary and renal endothelial cell injury linked to in

7 and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary

8 of positive PE diagnoses/total number of CT pulmonary angiographic examinations) was compared in pat

9 The yield of CT pulmonary angiography (number of positive PE diagnoses/t

10 viders overrode CDS alerts (by performing CT pulmonary angiography in patients with a Wells score </=

11 (CDS) for ordering computed tomographic (CT) pulmonary angiography in the emergency department (ED).

12 n whom providers followed Wells criteria (CT pulmonary angiography only in patients with Wells score

13 Pulmonary arterial compliance did not independently pred

14 Recent studies have suggested that pulmonary arterial compliance may also predict prognosis

15 ynamic variables during follow-up, including pulmonary arterial compliance, after initial management

16 osis factor alpha) in circulating monocytes, pulmonary arterial endothelial cells, and also activated

17 In familial pulmonary arterial hypertension (FPAH), the autosomal do

18 l efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described.

19 onsistently been associated with survival in pulmonary arterial hypertension (PAH) at the time of dia

20 of cardiovascular risk, however, its role in pulmonary arterial hypertension (PAH) has not been deter

21 r system, to seek evidence for alteration in pulmonary arterial hypertension (PAH) in which apelin si

22 RATIONALE: Pulmonary arterial hypertension (PAH) is an obstructive

23 Pulmonary arterial hypertension (PAH) is an obstructive

24 nce-based treatment guidelines for pediatric pulmonary arterial hypertension (PAH) is hampered by lac

25 lure, but whether it would be beneficial for pulmonary arterial hypertension (PAH) remains to be expl

26 n linked to occlusive vascular remodeling in pulmonary arterial hypertension (PAH) that is hereditary

27 reasingly recognized as a cause of angina in pulmonary arterial hypertension (PAH).

28 rolled patients with idiopathic or heritable pulmonary arterial hypertension from London (UK; cohorts

29 aired samples from 43 incident patients with pulmonary arterial hypertension in cohort 3 (p=0.0133).

30 in 93 patients with idiopathic or heritable pulmonary arterial hypertension in cohort 4, with 4.4 ye

31 val in patients with idiopathic or heritable pulmonary arterial hypertension to improve risk stratifi

32 rformed in 35 patients who were treated with pulmonary arterial hypertension-targeted therapies befor

33 ental to well-validated prognostic scores in pulmonary arterial hypertension.

34 oppler estimates and invasive measurement of pulmonary arterial pressure at rest and peak exercise we

35 H based on QRS-gated DPD demonstrated higher pulmonary arterial pressures versus isolated postcapilla

36 The polymeric particles were safe to rat pulmonary arterial smooth muscle cell and to the lungs,

37 In parallel, pulmonary arterial smooth muscle cells (PASMCs) from Cox

38 FbetaR-2 and phosphorylated SMAD2/3 in human pulmonary arterial smooth muscle cells on treatment with

39 ventricular preload and afterload influence pulmonary arterial wave propagation as demonstrated by c

40 Histologically, lungs showed ectatic pulmonary arteries and pulmonary veins.

41 Considering the dilation of the pulmonary arteries as a paramount sign of PAH, we hypoth

42 s an obstructive disease of the precapillary pulmonary arteries.

43 mechanical interaction with the dilated main pulmonary artery (MPA).

44 of LMCA extrinsic compression from a dilated pulmonary artery (PA) in patients with PAH and angina or

45 Remote monitoring of pulmonary artery (PA) pressures provides clinicians with

46 atrial switch operation) or 2-stage repairs (pulmonary artery band followed by arterial switch operat

47 by transducing a peripheral intravenous and pulmonary artery catheter, respectively, after zeroing a

48 eas current data support the notion that, in pulmonary artery endothelial cells (PAECs), expression o

49 Diastolic pulmonary artery pressure and mean PAWP were measured to

50 edicare claims data from patients undergoing pulmonary artery pressure sensor implantation between Ju

51 Pulmonary hypertension (mean pulmonary artery pressure, >/=25 mm Hg) was present in 8

52 g 29 (18%) regarded as moderate-severe (mean pulmonary artery pressure, >/=35 mm Hg) and 28 (34%) als

53 ate the DPD as per usual practice (diastolic pulmonary artery pressure-mean PAWP).

54 with a significantly greater number of small pulmonary artery side branches <300 mum per cm vessel (3

55 tive vasculopathy characterized by excessive pulmonary artery smooth muscle cell (PASMC) proliferatio

56 pha) is increased, the role of HIF-1alpha in pulmonary artery smooth muscle cells (PASMCs) remains co

57 vage via the sheddases, ADAM10 and ADAM17 in pulmonary artery smooth muscle cells (PASMCs).

58 ts in the 30 mg group died during the study (pulmonary artery thrombosis and cardiorespiratory failur

59 lling pressures with exercise, and depressed pulmonary artery vasodilator reserve.

60 eous respiration and dynamic stress tests on pulmonary artery wave propagation and reservoir function

61 ated, potentially related to the use of mean pulmonary artery wedge pressure (PAWP).

62 ontribute to therapeutic failure in invasive pulmonary aspergillosis (IPA).

63 Ninety-nine patients (71 with pulmonary atresia with intact ventricular septum and 28

64 Patients with pulmonary atresia with intact ventricular septum deemed

65 d BT shunt for infants with ductal-dependent pulmonary blood flow adjusted for differences in patient

66 e RAF/MEK/ERK pathway, have been reported in pulmonary, but not in nonpulmonary, LCH cases, suggestin

67 n on echocardiography, ratio of right atrial/pulmonary capillary wedge pressure, hemoglobin) was crea

68 dating epigenetic mechanisms contributing to pulmonary carcinogenesis and highlight ASXL3 as a novel

69 d nanoparticle-based drug delivery in murine pulmonary carcinoma.

70 e also suffered no bacteremia and survived a pulmonary challenge that was lethal to wild-type mice.

71 ced lung inflammation in mice upon high-dose pulmonary challenge with S. pneumoniae The cPLA2alpha-de

72 Upon acquirement of pulmonary circulation, the ancestral heart may have been

73 airway pressures, hypercarbia, and decreased pulmonary compliance.

74 morbidity (>/=grade III), mostly related to pulmonary complications (25.7%), anastomotic leakage (15

75 Postoperative pulmonary complications are common in patients with Amer

76 1.7 to 2.0) and a median 1.7 (IQR, 1.0-2.0) pulmonary complications score vs 2.1 (95% CI, 2.0-2.3) a

77 toperative recovery and a marked decrease in pulmonary complications.

78 was WHO-defined radiological pneumonia with pulmonary consolidation.

79 Pulmonary critical care fellows performed and documented

80 Pulmonary/critical care fellows.

81 To identify phenotypes of rapid pulmonary decline and determine how these phenotypes are

82 tion, TH2-associated cytokine synthesis, and pulmonary dendritic cell activity was assessed.

83 We found that Dll4 was expressed on CD11b(+) pulmonary dendritic cells in the lung and draining lymph

84 mice display a higher frequency of CD11b(+) pulmonary dendritic cells than their WT controls at the

85 ique resource and deeper insight into normal pulmonary development.

86 Chronic obstructive pulmonary disease (COPD) comprises chronic bronchitis an

87 s in blood and sputum in chronic obstructive pulmonary disease (COPD) have been associated with incre

88 Chronic obstructive pulmonary disease (COPD) is characterized by reduced lun

89 Chronic obstructive pulmonary disease (COPD) is regarded as a disease of acc

90 on risk in patients with chronic obstructive pulmonary disease (COPD) rely on a history of two or mor

91 therapeutic efficacy in chronic obstructive pulmonary disease (COPD).

92 ne expression studies in chronic obstructive pulmonary disease (COPD).

93 with worse outcomes than chronic obstructive pulmonary disease (COPD).

94 re in conditions such as chronic obstructive pulmonary disease (COPD).

95 robustly associated with chronic obstructive pulmonary disease (COPD).

96 ct conditions, including chronic obstructive pulmonary disease (COPD).

97 nhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

98 allergy (P = 0.045) and chronic obstructive pulmonary disease (COPD; P = 0.015).

99 tic treatment and with no history of chronic pulmonary disease or use of asthma medication in the pas

100 y due to respiratory and chronic obstructive pulmonary disease specifically were positive but impreci

101 Second neoplasms, spinal disorders, and pulmonary disease were major contributors to the excess

102 , stroke, pneumonia, and chronic obstructive pulmonary disease) and a surgical diagnosis (hip fractur

103 onic kidney disease, and chronic obstructive pulmonary disease).

104 seases including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis.

105 in children and adults, chronic obstructive pulmonary disease, hypertension, diabetes, obesity, perc

106 aired ejection fraction, chronic obstructive pulmonary disease, peripheral vascular disease, or renal

107 dicate an early stage of chronic obstructive pulmonary disease.

108 both cystic fibrosis and chronic obstructive pulmonary disease.

109 R 1.71; asthma: OR 1.56; chronic obstructive pulmonary disease: OR 1.65; cancer: OR 1.23; weak/failin

110 eumatoid arthritis, asthma, atherosclerosis, pulmonary diseases and Crohn's disease as hubs and thus

111 the effects of therapeutic interventions in pulmonary diseases.

112 ctomy is closely associated with reperfusion pulmonary edema occurrence in the next 48 hours (area un

113 s of respiratory mechanics, blood gases, and pulmonary edema.

114 t (n=2), and acute RV dysfunction with flash pulmonary edema.

115 bition system assembled at the site of acute pulmonary emboli in vivo.

116 f key fibrinolytic molecules in experimental pulmonary emboli, assessed the contribution of alpha2-an

117 yed fixation suffered 2-fold higher rates of pulmonary embolism (2.6% versus 1.3%; rate ratio [RR] 2.

118 Pulmonary embolism (PE) is a serious and prevalent cause

119 C) filters are widely used for prevention of pulmonary embolism (PE).

120 esence or absence of deep vein thrombosis or pulmonary embolism at the time of IVC filter placement.

121 Risk stratification for acute pulmonary embolism using imaging presence of right ventr

122 Pulmonary embolism was induced by jugular vein infusion

123 ism (which includes deep vein thrombosis and pulmonary embolism), but the evidence is uncertain.

124 myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).

125 Of these, 3 events-syncope, pulmonary embolism, and serum creatinine increase-in 3 p

126 In patients with hemodynamically significant pulmonary embolism, physiological fibrinolysis fails to

127 osite of symptomatic deep-vein thrombosis or pulmonary embolism, progression or recurrence of superfi

128 lasmin, may have unique therapeutic value in pulmonary embolism.

129 ciated with certain causes of arrest such as pulmonary embolism.

130 lar size and function in patients with acute pulmonary embolism.

131 (60 mg) had cycle 1 dose-limiting toxicity (pulmonary embolus).

132 antly increased between the first hour after pulmonary endarterectomy and day 2 (10.2 +/- 2.6 vs 11.4

133 EVLWPBW measured at the first hour after pulmonary endarterectomy is closely associated with repe

134 o inflammatory diseases, the role of EBI2 in pulmonary eosinophilia is unknown.

135 ease outcome, focused on the hypothesis that pulmonary eosinophilia linked with allergic respiratory

136 st study of the biological effects of LCs on pulmonary epithelia and our observations strongly sugges

137 enzymes were noncytotoxic and protected A549 pulmonary epithelial cells from A. fumigatus-induced cel

138 the receptor was predominantly expressed on pulmonary epithelium and on polymorphonuclear neutrophil

139 nflammation with a predominant effect on the pulmonary epithelium and PMNs.

140 In vivo, Runx2 was induced by 6.2-fold in pulmonary epithelium of house dust mite-challenged mice.

141 of child residence during the year prior to pulmonary evaluation.

142 e during the week, month, and 12 mo prior to pulmonary evaluation.

143 The annualised pulmonary exacerbation rate in patients continuing treat

144 he most common adverse events were infective pulmonary exacerbations, cough, increased sputum, and ha

145 The LCI worsened during cough episodes and pulmonary exacerbations, whereas similar symptoms in hea

146 stic fibrosis (CF) experience frequent acute pulmonary exacerbations, which lead to decreased lung fu

147 to detect response to antibiotic therapy for pulmonary exacerbations.

148 Pulmonary exposure to multiwalled carbon nanotubes (MWCN

149 Inflammation increased pulmonary expression of CXCR7, and the receptor was pred

150 isseminates and the animals develop a severe pulmonary failure, as demonstrated by lung mechanics and

151 g biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could part

152 Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung d

153 Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and f

154 Idiopathic pulmonary fibrosis (IPF) is a disease characterized by t

155 Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal inte

156 Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal inte

157 Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a

158 ung microbial community influence idiopathic pulmonary fibrosis (IPF) progression.

159 on and apoptosis are important in idiopathic pulmonary fibrosis and asbestosis.

160 o VEGF-Axxxb, are critical in development of pulmonary fibrosis and may be a paradigm for the regulat

161 s congenita, aplastic anemia, and idiopathic pulmonary fibrosis disrupt the binding between the prote

162 Idiopathic pulmonary fibrosis is a prototype of chronic, progressiv

163 ast differentiation/activation in idiopathic pulmonary fibrosis remain poorly understood.

164 ibutes to the development and progression of pulmonary fibrosis through its regulation of ADORA2B exp

165 Over time, these mice develop spontaneous pulmonary fibrosis, which is ameliorated by restoration

166 ated genes previously implicated in familial pulmonary fibrosis-as significant contributors to sporad

167 a promising candidate for in vivo imaging of pulmonary fibrosis.

168 nship with disease progression in idiopathic pulmonary fibrosis.

169 , chronic obstructive pulmonary disease, and pulmonary fibrosis.

170 nts with IPF and mice with bleomycin-induced pulmonary fibrosis.

171 the impact of maternal smoking on offspring pulmonary function and decrease the incidence of wheeze

172 Changes from baseline in pulmonary function at Week 48 were analyzed by emphysema

173 All measures considered for pulmonary function met consensus criteria for exclusion.

174 tudy subjects, which included laboratory and pulmonary function studies, chest computed tomography, a

175 evelop a new Technical Standard on reporting pulmonary function test results.

176 malignancy, and had available pretransplant pulmonary function test results.

177 roup performance status of 0-2, and adequate pulmonary function.

178 Intravenous injection of IL-33 or pulmonary fungal allergen challenge mobilized ILC2 proge

179 We used pulmonary gas exchange and (31) P magnetic resonance spe

180 plantation (LT), early prediction of grade 3 pulmonary graft dysfunction (PGD) remains a research gap

181 ssue and senescent cell deletion rejuvenates pulmonary health in aged mice.

182 events occurred in 4 cases (15%), including pulmonary hemorrhage, hypotension requiring vasoactive s

183 Chronic thromboembolic pulmonary hypertension (CTEPH) was confirmed in 4 (2.1%)

184 hysiological basis of chronic thromboembolic pulmonary hypertension (CTEPH) will be accelerated by an

185 Pulmonary hypertension (mean pulmonary artery pressure,

186 rial pressures versus isolated postcapillary pulmonary hypertension (P<0.05).

187 RATIONALE: Pediatric pulmonary hypertension (PH) is a heterogeneous condition

188 ft heart disease is the most common cause of pulmonary hypertension (PH).

189 ylcholinesterase inhibition, in experimental pulmonary hypertension (PH).

190 In contrast, chronic hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling

191 d mechanisms of right ventricular failure in pulmonary hypertension could be predicted by using super

192 hophysiology, and management implications of pulmonary hypertension in patients with obstructive hype

193 t reveal significant differences in residual pulmonary hypertension or RV dysfunction.

194 In pulmonary hypertension patients, the asymptotic pressure

195 ation, 63 years +/- 17) with newly diagnosed pulmonary hypertension underwent cardiac magnetic resona

196 lmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic ki

197 In pulmonary hypertension, the right ventricle adapts to th

198 ent knowledge on the use of beta-blockers in pulmonary hypertension.

199 y introduced as a novel treatment option for pulmonary hypertension.

200 rom the Dutch National Network for Pediatric Pulmonary Hypertension.

201 for understanding the changes that occur in pulmonary hypertension.

202 f subsets of patients with heart failure and pulmonary hypertension.

203 Bacterial burden and pulmonary immunopathology of chimeric mice lacking TLR2

204 in almost all patients with chronic cavitary pulmonary infections, chronic invasive and granulomatous

205 ith increased eosinophil activity, recurrent pulmonary infections, or both, as evident by the concomi

206 ) from arachidonic acid (AA), promotes acute pulmonary inflammation and systemic infection after lung

207 on with a PT-deficient strain induced severe pulmonary inflammation but not mortality in neonatal mic

208 suggest that A-SAA is functionally linked to pulmonary inflammation in our O3 exposure model and that

209 l the respective role of chronic hypoxia and pulmonary inflammation on soleus muscle hypertrophic cap

210 Pulmonary inflammation totally inhibited this hypertroph

211 ed the pivotal role of the receptor CXCR7 in pulmonary inflammation with a predominant effect on the

212 4c(-/-) CD19(+)CD138(+) cells induced marked pulmonary inflammation, eosinophilia, and increased bron

213 maging of the lungs is feasible and reflects pulmonary inflammation.

214 uate the influence of SD on allergen-induced pulmonary inflammation.

215 ic effects of extracellular histones in that pulmonary injury during influenza was exacerbated.

216 show the dominance and importance of robust pulmonary intravascular macrophage clearance of nanopart

217 , suggesting that each oncogene may initiate pulmonary LCH by transforming different types of lung-re

218 s potential therapeutics against a subset of pulmonary LCH.

219 y in the anterior segment of the right upper pulmonary lobe suggestive of alveolar hemorrhage.

220 incidence and duration of air leakage after pulmonary lobectomy for malignancy.

221 We have previously implicated activation of pulmonary macrophage by TNF-alpha and/or MCP-1 in the me

222 ed in C. neoformans phagocytosis by resident pulmonary macrophages and DC.

223 or latency (262 vs. 293 vs. 225 days), fewer pulmonary metastases (5 vs. 7 vs. 15), and differences i

224 ondary to the development and progression of pulmonary metastases remains a significant problem.

225 thereby limiting NK cell-mediated control of pulmonary metastases.

226 expression on CD8(+) T cells and limited B16 pulmonary metastasis to the same degree as PD-1 gene def

227 cid (DTPA)-labetuzumab-IRDye800CW can detect pulmonary micrometastases in a mouse model.

228 In human pulmonary microvascular endothelial cells, G was 20.4 +/

229 The quantification of pulmonary molecular imaging data remains challenging bec

230 y reflexes - carotid body glomus cells, and 'pulmonary neuroendocrine cells' (PNECs) - are obscure.

231 show decreased vascular permeability, fewer pulmonary neutrophils, and a reduction in levels of neut

232 that CB2 activation is crucial in regulating pulmonary NK cell function, and suggest that NK cells se

233 IMI identified 56 of 59 (94.9%) malignant pulmonary nodules identified by preoperative imaging.

234 ly predict the presence of EGFR mutations in pulmonary nodules of the adenocarcinoma spectrum.

235 In conclusion, pulmonary NTM disease is a neglected and emerging public

236 he same questions addressed by IOM-compliant pulmonary or critical care guidelines were addressed by

237 confirmed by the endpoint review committee), pulmonary or extrapulmonary tuberculosis, or any bacteri

238 Comorbid conditions can be pulmonary or extrapulmonary.

239 ox4i2 is essential for acute but not chronic pulmonary oxygen sensing by triggering mitochondrial hyp

240 exercise, intermittent exercise dissociates pulmonary oxygen uptake (VO2) from the accumulated work.

241 opportunistic and frequently drug-resistant pulmonary pathogen especially in cystic fibrosis suffere

242 on (AF) risk, including left ventricular and pulmonary pathology, systemic inflammation, and neurohor

243 visceral involvement using the ePOST (extra-pulmonary Physician Organ Severity Tool) severity score

244 n echocardiographic and invasive measures of pulmonary pressures during upright exercise is good amon

245 hat distinguish subjects with latent (LTBI), pulmonary (PTB) or extrapulmonary (EPTB) tuberculosis re

246 er surgical RV revalvulation for significant pulmonary regurgitation (n=21).

247 Pulmonary rehabilitation (PR) improves exercise capacity

248 point inhibitor molecule PD-L1 during type 2 pulmonary responses.

249 discoordination may contribute to long-term pulmonary right ventricular (RV) dysfunction in patients

250 Pulmonary SCFAs correlated with increased oral anaerobes

251 synergistic increase in the proliferation of pulmonary smooth muscle cells on exposure to HIV-protein

252 inistered sildenafil particles elicited more pulmonary specific and sustained vasodilation in SUGEN-5

253 esents a valid approach that can improve the pulmonary status and prevent further episodes of hemopty

254 g, such as dipalmitoylphosphatidylcholine in pulmonary surfactant; however, many of the roles of spec

255 pids, and proteins, a composition similar to pulmonary surfactants.

256 Pulmonary symptoms with eosinophilia are most common, th

257 We further find that after pulmonary TB infection, it still takes many days before

258 Xpert Ultra cartridge for diagnosis of adult pulmonary TB may have different consequences in differen

259 nes in participants with previous or current pulmonary TB may have the potential for causing harmful

260 All patients developed pulmonary TB, either alone or with extrapulmonary diseas

261 Consistent with this, in a pulmonary thromboembolism model, larger vessels were occ

262 Components of e-cigarette aerosol have known pulmonary toxicity.

263 One hundred patients with pulmonary tuberculosis (65% human immunodeficiency virus

264 Mycobacterium tuberculosis causes pulmonary tuberculosis (TB) and claims 1.8 million huma

265 Of 12 culture-confirmed pulmonary tuberculosis cases identified among children w

266 intermittent dosing schedules in first-line pulmonary tuberculosis therapy.

267 CASE REPORT: A young woman with pulmonary tuberculosis was found to have disseminated tu

268 c testing for latent tuberculosis infection, pulmonary tuberculosis, and extrapulmonary tuberculosis

269 nexposed control subjects, and patients with pulmonary tuberculosis.

270 Submillimeter pulmonary tumor colonies could be visualized with both s

271 rall TAM density is different among separate pulmonary tumour models, nanotherapeutic drug delivery c

272 The incidence of Melody transcatheter pulmonary valve stent fracture (3.4%) and infectious end

273 mechanistically study transfusion-associated pulmonary vascular complications in susceptible patient

274 l assessment of the diagnosis of cardiac and pulmonary vascular disease and interventions aimed at ma

275 This suggests that pulmonary vascular disease is a key mechanism underlying

276 tudy provides insights into the influence of pulmonary vascular disease, spontaneous respiration and

277 the open lung approach resulted in the best pulmonary vascular mechanics compared with higher or low

278 Pulmonary vascular remodeling severity was associated wi

279 th HF-PH with right ventricular dysfunction, pulmonary vascular remodeling was not more severe.

280 c hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling were not or only slightly

281 In HF, PH is associated with global pulmonary vascular remodeling, but the severity of PH co

282 >/=35 mm Hg) and 28 (34%) also had increased pulmonary vascular resistance >3.0 WU.

283 /- 7 versus 47 +/- 10 mm Hg, P < 0.0001) and pulmonary vascular resistance (3.0 +/- 1.4 versus 6.1 +/

284 lary PH with elevated vascular gradients and pulmonary vascular resistance defines combined post- and

285 ater can also occur in the setting of normal pulmonary vascular resistance from a high flow state and

286 tely describe the changing properties of the pulmonary vascular system and the right ventricle, as we

287 the pathophysiology and target treatments to pulmonary vascular tone in this population.

288 tem/stromal cells (ASCs) for engineering the pulmonary vasculature in a decellularized rat lung scaff

289 Ablation was performed by circumferential pulmonary vein isolation plus linear ablation of extrapu

290 fibrillation after contact force (CF)-guided pulmonary vein isolation.

291 Pulmonary vein reconnection (PVR) still determines recur

292 nal MIL design, connecting the left inferior pulmonary vein with the mitral annulus.

293 f cryotherapy during cryoballoon ablation of pulmonary veins is still unclear.

294 ong candidate gene as it is expressed in the pulmonary veins, a source of AF in many individuals.

295 lungs showed ectatic pulmonary arteries and pulmonary veins.

296 ve peripheral blood (PPB) and intraoperative pulmonary venous blood (IPVB) could predict poor long-te

297 56+/-0.19 and 0.53+/-0.20; P=0.0004), higher pulmonary venous pressure relative to left ventricular t

298 Increased pulmonary venous pressure secondary to left heart diseas

299 ance from a high flow state and/or increased pulmonary venous volume.

300 anical ventilation and was discharged to the pulmonary ward, followed by complete recovery.